In the BioHarmony Drug Report Database
Mepolizumab
Nucala (mepolizumab) is an antibody pharmaceutical. Mepolizumab was first approved as Nucala on 2015-11-04. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma. The pharmaceutical is active against interleukin-5.
Trade Name
|
Nucala |
|---|---|
Common Name
|
mepolizumab |
ChEMBL ID
|
CHEMBL2108429 |
Indication
|
asthma |
Drug Class
|
Monoclonal antibodies: humanized, immunomodulating |
Image (chem structure or protein)
